PROJECT TEAM
Frederik Clausen, Senior Research Scientist, Copenhagen University Hospital
THE NEED
Organ rejection remains a major challenge after transplantation, affecting up to 50% of patients within two years. Current monitoring methods, such as invasive biopsies or unreliable blood markers, fail to detect organ damage early enough for timely treatment. There is a critical need for a reliable, noninvasive tool that can predict rejection before irreversible harm occurs.
THE SOLUTION
Our solution measures cfDNA released by damaged organs directly from a blood sample. This enables early and accurate detection of organ rejection, often months before current methods can detect any issue. The test allows repetitive monitoring, guiding personalized adjustment of immunosuppressive therapy (precision medicine) and reducing the need for invasive procedures. Results are delivered within one working day.
DNA-Analyse: Testing of donor-derived cell-free DNA as a noninvasive marker for organ damage in transplantation patients - Rigshospitalet
Call 2 - 2022
500.000 DKK
Clinical Area
Transplantation
Technology
Blood test
PROJECT SUMMARY
The DNA-Analyse project develops a novel blood test that measures organ-derived cell-free DNA (cfDNA) as a precise and early marker of organ damage or rejection in transplantation patients. This noninvasive method aims to improve monitoring, guide treatment, and prolong both organ and patient survival.
CLINICAL IMPACT
The test improves patient care by enabling early intervention, which can prolong organ survival and reduce the risk of complications. It also enhances patient quality of life by replacing painful biopsies with a simple blood test. Clinicians gain a fast and reliable tool to monitor organ health, optimize treatment, and prevent hospitalizations.